Plus Therapeutics Bolsters REYOBIQ Manufacturing with SpectronRx Partnership
Event summary
- Plus Therapeutics has initiated manufacturing activities for REYOBIQ with SpectronRx under a Master Services Agreement (MSA).
- SpectronRx will serve as a second GMP manufacturing site, complementing Radiomedix.
- Telix Pharmaceuticals will continue to supply Rhenium-186 isotope.
- The MSA includes technology transfer for REYOBIQ manufacturing, isotope processing, and analytical methods.
- SpectronRx’s Indiana facility will offer on-demand production of both Rhenium-186 and REYOBIQ.
The big picture
The agreement highlights the growing complexity and capital intensity of radiopharmaceutical development, where securing reliable manufacturing capacity is paramount for clinical advancement. Radiopharmaceutical companies are increasingly reliant on specialized contract manufacturers like SpectronRx to meet the demands of late-stage trials and potential commercialization. This move underscores Plus Therapeutics’ commitment to de-risking its REYOBIQ program and ensuring sufficient supply for pivotal trials, a common strategy in the sector as companies move beyond early-stage development.
What we're watching
- Execution Risk
- The successful technology transfer from Plus Therapeutics to SpectronRx will be critical; delays or complications could impact the timeline for late-stage clinical trials.
- Supply Chain
- The reliance on three key partners (SpectronRx, Radiomedix, and Telix) creates a concentrated supply chain; any disruption at one partner could significantly impact REYOBIQ production.
- Regulatory Scrutiny
- As Plus Therapeutics scales up manufacturing, increased regulatory scrutiny from the FDA and EMA is likely, potentially impacting timelines and costs.
Related topics